Weilheim, Germany

Anton Haselbeck

USPTO Granted Patents = 2 



Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 17(Granted Patents)


Company Filing History:


Years Active: 1993-2010

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Anton Haselbeck: Innovator in Erythropoietin Research

Introduction

Anton Haselbeck is a notable inventor based in Weilheim, Germany. He has made significant contributions to the field of biochemistry, particularly in the development of erythropoietin (EPO) compositions. With a total of 2 patents, his work has had a considerable impact on medical research and applications.

Latest Patents

Haselbeck's latest patents include innovative compositions of erythropoietin with high specific activity. These compositions are characterized by a high proportion of N-acetyl-lactosamine units and/or tetraantennary branches in their carbohydrate structure. Additionally, he has developed a process for detecting compounds containing carbohydrates. This process involves reacting the compound to be detected with a conjugate that enables specific binding to the substance, followed by interaction with labeled antibodies directed against the hapten.

Career Highlights

Throughout his career, Anton Haselbeck has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Roche Diagnostics GmbH and Boehringer Mannheim GmbH. His experience in these organizations has allowed him to refine his expertise and contribute to groundbreaking research.

Collaborations

Haselbeck has collaborated with esteemed colleagues in his field, including Josef Burg and Karl-Heinz Sellinger. These partnerships have fostered an environment of innovation and have led to advancements in the understanding and application of erythropoietin.

Conclusion

Anton Haselbeck's contributions to the field of biochemistry, particularly in erythropoietin research, highlight his role as an influential inventor. His patents and collaborations reflect a commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…